- Home
- RDWR vs ETNB Comparison
RDWR vs ETNB Comparison
Compare RDWR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- ETNB
- Stock Information
- Founded
- RDWR 1996
- ETNB 2018
- Country
- RDWR Israel
- ETNB United States
- Employees
- RDWR N/A
- ETNB N/A
- Industry
- RDWR EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- ETNB Health Care
- Exchange
- RDWR Nasdaq
- ETNB Nasdaq
- Market Cap
- RDWR 889.9M
- ETNB 1.0B
- IPO Year
- RDWR 1999
- ETNB 2019
- Fundamental
- Price
- RDWR $19.48
- ETNB $4.85
- Analyst Decision
- RDWR Hold
- ETNB Strong Buy
- Analyst Count
- RDWR 4
- ETNB 10
- Target Price
- RDWR $27.00
- ETNB $27.56
- AVG Volume (30 Days)
- RDWR 139.1K
- ETNB 2.4M
- Earning Date
- RDWR 05-07-2025
- ETNB 05-08-2025
- Dividend Yield
- RDWR N/A
- ETNB N/A
- EPS Growth
- RDWR N/A
- ETNB N/A
- EPS
- RDWR 0.14
- ETNB N/A
- Revenue
- RDWR $274,880,000.00
- ETNB N/A
- Revenue This Year
- RDWR $9.54
- ETNB N/A
- Revenue Next Year
- RDWR $7.54
- ETNB N/A
- P/E Ratio
- RDWR $141.50
- ETNB N/A
- Revenue Growth
- RDWR 5.20
- ETNB N/A
- 52 Week Low
- RDWR $16.12
- ETNB $4.75
- 52 Week High
- RDWR $25.00
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- RDWR 29.97
- ETNB 32.14
- Support Level
- RDWR $18.46
- ETNB $7.66
- Resistance Level
- RDWR $20.49
- ETNB $7.30
- Average True Range (ATR)
- RDWR 0.75
- ETNB 0.76
- MACD
- RDWR -0.32
- ETNB -0.21
- Stochastic Oscillator
- RDWR 20.67
- ETNB 5.84
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).